IN THE CLAIMS

The following listing of claims will replace all prior versions and listings, of claims in this application:

Claims 1-10 (Canceled).

- 11. (Currently Amended) A method for intranasally administering a composition comprising a microparticle having a protein and an antibody adsorbed thereon, wherein said administering comprises contacting a microparticle having a protein and an antibody thereon with the nasal mucosa of a patient in need thereof, wherein said antibody is an immunoglobulin specific for the protein, and wherein the composition is absorbed through the nasal mucosa of the patient more than contacting the composition through intestinal mucosa of the patient.
- 12. (Previously Presented) The method of Claim 11, wherein said protein is selected from the group consisting of BSA, insulin, enkephalin, hormones, growth factors, cytokines, coagulation factors, polypeptides, and antimicrobial agents.
- 13. (Previously Presented) The method of Claim 11, wherein said antibody is an immunoglobulin selected from the group consisting of IgM, IgA, and IgG.

Claim 14 (Cancelled).

- 15. (Previously Presented) The method of Claim 11, wherein said microparticle is biodegradable.
- 16. (Previously Presented) The method of Claim 11, wherein said microparticle comprises polystyrene.
- 17. (Previously Presented) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 15,000 moles of protein per mole of antibody.
- 18. (Previously Presented) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 5,000 moles of protein per mole of antibody.

- 19. (Previously Presented) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 100 moles of protein per mole of antibody.
- 20. (Previously Presented) A method for intranasally administering a composition comprising a microparticle and an antibody adsorbed thereon, wherein said administering comprises having a protein and an antibody thereon with the nasal mucosa of a patient in need thereof, and wherein the transepithelial transport obtained with 3.2×10^{11} microparticles/ml is 1.7%, wherein said antibody is an immunoglobulin specific for the protein.
- 21. (Previously Presented) The method of Claim 20, wherein said protein is selected from the group consisting of BSA, insulin, enkephalin, hormones, growth factors, cytokines, coagulation factors, polypeptides, antimicrobial agents.
- 22. (Previously Presented) The method of Claim 20, wherein said antibody is an immunoglobulin selected from the group consisting of IgM, IgA, and IgG.

Claim 23 (Cancelled).

- 24. (Previously Presented) The method of Claim 20, wherein said microparticle is biodegradable.
- 25. (Previously Presented) The method of Claim 20, wherein said microparticle comprises polystyrene.
- 26. (Previously Presented) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 15,000 moles of protein per mole of antibody.
- 27. (Previously Presented) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 5,000 moles of protein per mole of antibody.
- 28. (Previously Presented) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 100 moles of protein per mole of antibody.